Furthermore, the administration of rifaximin for 4–12 weeks has been shown to decrease the blood levels of IL-6, IL-10, and TNF-α in patients with nonalcoholic fatty liver disease and cirrhosis with HE [47,48,49]. The gene discussed is IL10; the disease is Cirrhosis.